Lv0
0 积分 2022-08-02 加入
Optimizing treatment for HER2-positive HR-positive breast cancer
1年前
已完结
Neoadjuvant Endocrine Therapy in Clinical Practice: A Review
1年前
已完结
Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer
2年前
已完结
Trastuzumab Deruxtecan in HER2-Low Breast Cancer
2年前
已完结
Connexins orchestrate progression of breast cancer metastasis to the brain by promoting FAK activation
2年前
已完结
Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer
2年前
已完结
Genomics to select treatment for patients with metastatic breast cancer
2年前
已完结
Improving breast cancer diagnostics with deep learning for MRI
2年前
已完结
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
2年前
已完结
Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study
2年前
已完结
皖公网安备34019202002308
